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ABSTRACT
AEG-1 KNOCKOUT SENSITIZES HEPATOCELLULAR CARCINOMA (HCC) CELLS
TO IONIZING RADIATION
A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science Virginia Commonwealth University, 2019
By MAHEEN H. KHAN, B.S.
ADVISOR: DR. DEVANAND SARKAR, M.B.B.S., Ph.D.
Professor, Department of Human and Molecular Genetics
Harrison Foundation Distinguished Professor in Cancer Research
Virginia Commonwealth University
Liver cancer is the fourth leading cause of cancer-associated deaths globally, and among primary
liver cancers, hepatocellular carcinoma (HCC) encompasses 75-85% of all cases. HCC is a
highly lethal disease due to limited treatment options – only a small subset of patients qualify for
surgical resection or transplantation; the remaining patients often display resistance to radiation
therapy or chemotherapy. Overexpression of the oncogene astrocyte elevated gene-1 (AEG-1) is
associated with poorer survival and increased tumor recurrence in HCC, and numerous studies
show its role in initiation of hepatocarcinogenesis. A prior study also demonstrated AEG-1
expression inhibits senescence by diminishing the ATM/Chk1/Chk2/p53/p21 DNA damage
response (DDR) pathway. The aim of this study is to understand if AEG-1 expression promotes
radioresistance in HCC. A CRISPR/Cas9 plasmid system was used to delete AEG-1 in the QGY7703, HuH7 and DihXY cell lines, which model HCC. The cell lines were then treated with
ionizing radiation (IR). We find that knockout of AEG-1 in these cell lines induces sensitivity to
IR at 2.5 Gy. In response to radiation, AEG-1 wildtype cells more profoundly upregulate ATR,
Chk1, and Chk2 signaling; and also more rapidly induce γH2AX, ATM, and BRCA1 signaling,
which sense dsDNA breaks to initiate homologous recombination repair. We conclude that
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AEG-1 expression protects HCC cells from IR through two mechanisms: 1) rapidly initiating the
DNA damage response; and 2) increasing replication fork stabilization. These findings indicate
AEG-1 can be a therapeutic target in combination with radiation treatment to improve outcomes
for HCC patients who demonstrate radioresistance.
Keywords: Hepatocellular carcinoma, ionizing radiation, astrocyte elevated gene-1, DNA
damage response
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CHAPTER 1
INTRODUCTION
Hepatocellular carcinoma
Liver cancer has the sixth highest incidence of all cancers globally, and is the fourth leading
cause of cancer-associated deaths. Among males, liver cancer is the second highest cause of
cancer-related deaths, and has the fifth highest incidence of all cancers. According to the most
recent global cancer statistics report, approximately 841,000 new cases of liver cancer and
782,000 liver-cancer-associated deaths are reported world-wide. The incidence of liver cancer is
increasing in Western nations due to the growing obesity epidemic in these areas – the incidence
of HCC is strongly associated with diabetes. Among primary liver cancers, hepatocellular
carcinoma (HCC) encompasses 75-85% of all cases1.
HCC is often an end-stage liver disease that is secondary to infection by hepatitis B virus (HBV)
or hepatitis C virus (HCV), both of which lead to chronic inflammation and liver cirrhosis. 50%
of all HCC cases are attributed to chronic HBV infection. On the other hand, the percentage of
HCC patients positive for HCV markers varies geographically, with Japan having the highest
percentage (80-90%). HCC is more prevalent among males partly due to increased incidence of
viral hepatitis and alcohol-induced cirrhosis; and partly due to hormonal differences, such as
association between increased testosterone and advanced hepatic cirrhosis, and the protective
effect of estrogen against HBV infection2.
Anti-viral treatment reduces recurrence and mortality in patients with HBV-associated HCC,
while interferon therapy decreases mortality in HCV-associated HCC. Localized HCC can be
treated with surgical resection, liver transplantation, and radiofrequency ablation. However, these

methods are not effective in tumors of advanced symptomatic stages. Systemic treatment of HCC
is difficult due to its resistance to traditional chemotherapies, including to cisplatin, doxorubicin,
and 5-fluorouracil. Sorafenib, a multi-kinase inhibitor that targets the serine/threonine kinase
RAF, is FDA-approved for systemic treatment of patients with advanced HCC; however, a
clinical trial showed survival was only improved from 7.9 to 10.7 months in sorafenib-treated
HCC patients. Chemotherapy and radiotherapy are now used as palliative treatment in patients
with metastatic HCC due to demonstrated resistance to both forms of treatment3,4. The limited
treatment options make HCC a highly lethal disease.
HCC initiates from terminally differentiated, rarely-dividing epithelial cells. The most frequent
genes mutated in HCC are those encoding the proteins p53, c-myc, cyclin D1, BRCA2, APC,
and PTEN, among others. Activation of the mitogen-activated protein kinase (MAPK) and
vascular endothelial growth factor (VGEF) pathways are also highly associated with HCC
tumorigenesis and development. Because HCC tumors show heterogeneity in their activated
oncogenic signaling pathways and in their mutated genes, it is difficult to establish effective
treatments for the disease4.
Radiation therapy and radioresistance in HCC patients
HCC patients who are not candidates for surgical resection of tumors, constituting some 85% of
the patient population, have various other options: radiation therapy, radiofrequency ablation,
percutaneous ethanol injection, microwave coagulation therapy, and transarterial
chemoembolization (TACE). For many years, clinicians were cautious to use radiation therapy
due to the risk of inducing radiation-induced liver disease, which can eventually lead to liver
failure. The risk of causing radiation-induced damage to nearby, uninvolved organs was also
present. Radiation therapy given in low doses (ranging from 8 to 50 Gy) originally played a
2

larger role in improving symptoms for patients in palliative care by treating lymph node, bone,
and brain metastases from primary HCC tumors. However, advances in imaging and delivery of
radiation therapy have increased the use of radiation therapy in the last twenty years for both
advanced and metastatic HCC patients. Combination of radiation therapy with TACE has been
suggested to improve 5-year survival and reduce recurrence rates following treatment5.
There are a number of methods of radiation delivery for HCC patients with varying overall
survival and recurrence rates. A 2012 Swiss study with a cohort of 138 patients assessed the
effectiveness of volumetric modulated arc therapy (VMAT) on modest tumor size. They report
the mean survival for HCC patients treated at 45, 60, and 66 Gy were 8.6, 13.5, and 25.9 months,
respectively, indicating effectiveness of radiation therapy increases in a dose-dependent manner.
However, complete response to radiation therapy was achieved in only 11% of the patients,
indicating resistance to treatment6. Three-dimensional conformal radiotherapy (3DCRT) is
another form of radiotherapy that has found promising results. In a French phase II clinical trial,
80% of patients treated with 3DCRT at 66 Gy were reported to have a complete tumor response.
Although the data is encouraging, 22% of internal lesions and 41% of external lesions were
recurrent after a mean follow-up of 29 months7. Furthermore, a metanalysis of clinical trials
using either stereotactic body radiotherapy, radiofrequency ablation, and TACE showed that the
highest 1-year overall survival for patients was 82%, while 1-year localized control varied
anywhere from 65 to 100%8.
The conflicting results from studies on treating HCC patients with radiation therapy make it
evident that investigating the molecular mechanisms leading to radioresistance of HCC tumors is
crucial for improving patient overall survival and reducing tumor recurrence. The identification
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and subsequent targeting of a biomolecule involved in tumor radioresistance is a promising
method of sensitizing HCC tumors to radiation treatment.
AEG-1 structure and function
Astrocyte elevated gene-1 (AEG-1), also known as MTDH or LYRIC, is an oncogene that was
initially cloned in primary human fetal astrocytes9,10. The AEG-1 locus is present on human
chromosome 8q22 and contains 12 exons and 11 introns11. AEG-1, which acts as a scaffolding
protein, contains 582 amino acids, with a 51-72 amino acid single-pass transmembrane domain,
and lacks identifiable functional or DNA-binding domains. However, an LXXLL motif present
in its N-terminal domain interacts with transcriptional coactivators and co-repressors, indicating
its function as a scaffolding protein12. All tissues ubiquitously express AEG-1 mRNA, although
skeletal muscle, heart, and endocrine gland tissues have higher basal expression13. AEG-1 is
expressed at low levels in wildtype hepatocytes, and is localized to the nucleus in these cells14. In
transformed HCC cells, AEG-1 is localized to the cellular perinuclear space. When stimulated by
TNF-α - an activator of the MAP kinase cascade and NF-κB survival pathways - AEG-1
translocates to the nucleus to act as a potential transcriptional co-activator of the CREB-binding
protein and NF-κB transcriptional complex15.
Overexpression of AEG-1 has been indicated in multiple cancer types, including HCC, breast,
prostate, non-small cell lung, and colorectal cancers16. AEG-1 overexpression in HCC was
established by immunostaining using anti-AEG-1 antibody and by microarray of patient HCC
liver samples. Primary HCC liver samples show increased AEG-1 staining when compared with
normal adjacent liver samples, and HCV-associated HCC tissues show a marked increase of
AEG-1 mRNA expression in contrast with normal and cirrhotic liver tissues. HCC-derived cell
lines have also been clearly characterized with AEG-1 overexpression. In vivo siRNA-mediated
4

downregulation of AEG-1 significantly suppresses the growth of xenografted HCC-derived
tumors11. AEG-1 knockout mice lack spontaneous liver tumor formation throughout their
lifespan, and treatment of AEG-1 knockout mice with diethylnitrosamine results in high
resistance to tumor formation compared to wildtype mice, further establishing AEG-1’s role in
liver carcinogenesis17. Analysis of patient HCC tissue samples corroborate in vitro and in vivo
studies by demonstrating a marked increase of AEG-1 mRNA and protein expression;
furthermore, AEG-1 expression levels in patients correlate with the stage and differentiation of
HCC11. Clearly, AEG-1 can be used as a diagnostic and prognostic marker, and as a potential
therapeutic target, in HCC.
AEG-1 promotes cancerous phenotypes through activation of several intracellular signaling
pathways. Hepatocytes derived from AEG-1 knockout mice show low activation of NF-κB,
indicating that AEG-1 is required for NF-κB activation17. In vitro upregulation of AEG-1
increases the migration and invasive profiles of HeLa and human glioma cell lines via activation
of the NF-κB pathway, while siRNA-mediated downregulation of AEG-1 or of NF-κB decreases
these characteristics15.
The Ras-Raf-MEK-ERK pathway, which regulates cell proliferation and growth in response to
extracellular signals such as mitogens, has also been indicated as a target for activation by AEG1. In AEG-1 overexpression clones, phosphorylated ERK42/44, p38 MAPK, and AKT
expression was significantly increased, although there was no change in phosphorylation of the
pro-apoptotic kinase JNK. Inhibition of ERK42/44 and p38 MAPK decreased in vitro matrigel
invasion of AEG-1 overexpression clones, but did not significantly affect proliferation11. Akt,
ERK1/2, and β-catenin are not regulated by AEG-1 as evidenced by a lack of difference in their
phosphorylated forms between AEG-1 KO and wildtype mice17. These studies show the role of
5

AEG-1 overexpression in promoting an aggressive cancerous phenotype by inducing invasive,
proliferative, and anchorage-independent growth characteristics, and by inhibiting pro-apoptotic
signaling.
Interestingly, AEG-1 has also been implicated in inhibiting senescence and dampening activation
of the DNA damage response (DDR) in hepatocytes. In a transgenic mouse model with
hepatocyte-specific expression of AEG-1, Srivastava et al. (2012) found that there was an
increased number of cells positive for b-galactosidase – a marker for senescence – in cultured
wildtype hepatocytes when compared to AEG-1 expressing hepatocytes. Subsequent protein
expression analysis of the DNA damage markers ataxia telangiectasia mutated (ATM) protein,
ATM and Rad3-related (ATR) protein, Chk1, and Chk2 demonstrated increased phosphorylation
of these proteins in the wildtype hepatocytes compared against AEG-1 overexpressing
hepatocytes. Therefore, AEG-1 expression may protect transformed hepatocytes from DDRinduced senescence12. There have not yet been follow-up studies to elucidate the mechanism
through which AEG-1 may directly or indirectly interact with the DDR signaling network.
Regardless, it is evident that AEG-1 has diverse roles in initiating hepatocarcinogenesis and
protecting transformed hepatic cells from cell death.
The Mammalian Cell Cycle
Eukaryotic cells can be in a dividing or non-dividing state. The non-dividing states include
quiescence, senescence, differentiation, and apoptosis. Quiescence is reversible - after receiving
mitogenic signals, such as cyclins D and E to de-repress E2F-dependent genes, quiescent cells
can re-enter the cell cycle. Differentiated and senescent cells, on the other hand, are permanently
withdrawn from the cell cycle. The genes involved in quiescence are a different subset of genes
compared to those upregulated during growth or apoptotic inhibition18.
6

Cyclin dependent kinases (Cdk’s) interact with various protein cyclins to temporally regulate the
phases of the cell cycle. The activity of these Cdk’s oscillate throughout the cell cycle and each
cell cycle phase involves formation of specific Cdk-cyclin complexes. Cdk’s regulate cell cycle
progression by binding various cyclins, including cyclins A, B, D, and E. Early G1 is regulated
by the cyclin D/cdk4 and cyclin D/cdk6 complexes, while S-phase initiation is regulated by
cyclins A and E expression19,20. The activated cyclin D/Cdk4/6 complex targets retinoblastoma
protein, pRb, whose phosphorylation results in progression through G1. Following
phosphorylation, pRb releases transcription factors of the E2F family, which activates cyclin E
transcription. Cyclin E can then form a complex with Cdk2 to further phosphorylate pRb and
promote G1 progression and S-phase entry21.
Entry into G2/M is regulated by a phosphorylation switch of Cdk/cyclin complexes. Protein
phosphatase 2A (PP2A) prevents entry into mitosis by dephosphorylating mitotic Cdk’s, and its
activity is downregulated in multiple cancer types. Cdc25 activates Cdc2-cyclin B which
promotes entry into M phase22. Cancer cells with defective G1/S checkpoints may rely on the
G2/M checkpoint to avoid apoptosis and continue cell proliferation23.
G0/G1 and G1/S checkpoints prevent inappropriate DNA replication, while G2/M checkpoint
allows for DNA repair. Two families of Cdk inhibitors negatively regulate the cell cycle: the
INK family binds cdk4 and cdk6 to inhibit D-type cyclin/cdk complex formation; and p21 which
inhibits kinase activity by binding cyclin/Cdk complexes. p21 can therefore inhibit cell cycle
progression at the G1/S boundary24.
The DNA Damage Response
DNA damage may result from a variety of intracellular and extracellular stimuli, and if not
resolved, may lead to genomic instability. Ionizing radiation (IR) is one such inducer of DNA
7

damage. The effects of IR can either be direct (i.e. DNA double-stranded breaks) or indirect
(formation of reactive oxygen and reactive nitrogen species). ROS and RNS can induce singlestranded DNA breaks (SSB’s) and double-stranded DNA breaks (DSB’s), DNA crosslinks, and
base damage. Surviving cells after IR will have progeny that are characterized by chromosomal
rearrangements, aneuploidy, gene amplification, altered gene expression, and other
characteristics of genetic instability25. Cells exposed to IR during S-phase are susceptible to
replication fork stalling and collapse, base mispairing, and point mutations. On the other hand,
IR exposure during mitosis can lead to loss of genetic material and cell death21.
Genomic instability can predispose a cell to initiating carcinogenesis. Homologous
recombination repair (HRR) and non-homologous end joining (NHEJ) are two repair pathways
present in mammalian cells that protect genomic integrity in the presence of genotoxic stressors.
While NHEJ repairs blunt DNA breaks without sequence homology, HRR restores doublestranded breaks and requires sequence homology in the form of a sister chromatid as a template.
HRR can only occur in S and G2 phases due to the availability of CDK1, which is needed for 5’3’ end processing and DNA synthesis recovery. NHEJ, on the other hand, can occur throughout
the cell cycle. Although the DNA repair pathways are compartmentalized to facilitate our
understanding of their mechanisms, there is likely crosstalk between the pathways. They can
complement, counteract, or overlap each other’s functions26.
HRR recruits a multitude of proteins to repair DSB’s. Following generation of a DSB, resection
of the 5’ end creates a 3’ single-stranded on each side of the DSB. Replication protein A (RPA)
coats the exposed single-stranded DNA (ssDNA), and is then replaced by Rad51 in a Rad54,
PALB2, BRCA2-dependent process. Strand invasion from the sister chromatid then occurs to
create a Holliday Junction. Cohesin proteins stabilize the strand invasion complex and promote
8

faithful HRR. DNA replication then ensues using the undamaged chromatid as a template27.
When HRR is insufficient in cells or if the number of DSB’s is too large for the cell to repair, the
cells are directed to apoptosis28.
In response to IR, ATM phosphorylates Mdm2/p53 and Chk2. Stabilization of p53 and its
subsequent transactivation of p21 is the slow (2-3 hour) response following IR and results in
inhibitory binding of both cyclin D/Cdk4/6 and cyclin E/Cdk2 complexes. Chk2 activation, on
the other hand, occurs much faster (<1 hour) and results in inactivation of Cdc25, which also
results in inhibitory phosphorylation of the cyclin E/Cdk2 complex21.
ATR is recruited to stalled replication forks and single-stranded DNA breaks by ATR-interacting
protein (ATRIP), which interacts with RPA-bound ssDNA via its acidic checkpoint recruitment
domain. The 9-1-1 complex - consisting of RAD9A, RAD9B, HUS1, and RAD1 – along with
DNA topoisomerase 2-binding protein (TOPBP1) are recruited to the single-stranded breaks.
TOPBP1 phosphorylates and activates ATR, which induces ATR’s kinase activity.
Subsequently, ATR activates Chk1 via phosphorylation and inactivates CDK1/2 activity29,30.
Breast cancer type 1 and 2 susceptibility proteins (BRCA1 and BRCA2) function in DSB repair
and control mitotic entry in the presence of DNA damage via control of the G2 checkpoint31.
BRCA1 coordinates MRN and CtIP complex formation, while BRCA2 stabilizes Rad51
filaments26.
PARP1 is another prominent player in NHEJ, HRR, and base mismatch repair pathways. Briefly,
PARP1 senses DSB’s and quickly recruits meiotic recombination 11 (MRE11) and Nijmegen
breakage syndrome 1 (NBS1) proteins to those sites. Once bound to sites of DNA damage,
PARP1 catalyzes the addition of poly(ADP-ribose) chains to itself in addition to DNA repair
9

enzymes and histones, and then recruits repair factors29. There is evidence that when PARP1 is
unavailable, single-stranded DNA breaks lead to stalled replication forks, which are then
converted to double-stranded breaks to be repaired by HRR32. However, elimination of PARP1
does not completely prevent activation of the DDR, suggesting that its role is redundant in these
complex pathways33.
TP53 is a tumor suppressor gene that acts as a central hub for numerous cellular processes,
including those controlling apoptosis, growth arrest, cell cycle progression, and DNA repair. The
protein product of TP53, p53, is coined the “guardian of the genome” due to its ability to induce
G1 arrest following DNA damage34. It is hypothesized that p53 mutation status determines the
survival fate of cells facing large amounts of DNA damage, while cells with smaller amounts of
DNA damage are able to appropriately repair DNA damage and begin cycling normally again.
Therefore, coordinating multiple signaling pathways is needed to decide whether a cell will
increase its DNA repair and survival response, or induce apoptosis, in response to ionizing
radiation35,36.
BCCIP structure and function, and AEG-1 interaction
BRCA2-and-p21-interacting protein (BCCIP) acts as a tumor suppressor gene and has been
shown to have a role in the DNA damage response during homologous recombination repair of
double-stranded DNA breaks in conjunction with BRCA2. BCCIP also promotes cell cycle arrest
at the G1/S checkpoint by enhancing the inhibition of CDK2 activity via binding of
CDKN1A/p21. Two isoforms of BCCIP exist in humans, BCCIPα and β, which contain identical
N-terminal domains and differ in their C-termini. Both isoforms are localized to the nucleus and
are ubiquitously expressed across skeletal muscle, heart, kidney, and brain tissues, among others.
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At the G1/S checkpoint and throughout S phase, both BCCIPα and BCCIPβ mRNA expression
peak. However, BCCIP’s role in interacting with p21 to promote cell cycle arrest is primarily
attributed to the α isoform37.
The clinical significance of BCCIP expression has been investigated in several human cancers,
including downregulation of both isoforms in multiple human kidney tumors38. In HCC, BCCIP
downregulation correlates with reduced survival, increased tumor size, and higher histological
grade of tumor in patients. Furthermore, in vitro knockdown of BCCIP in human-derived
hepatocytes promotes cell proliferation, confirmed by accelerated G1 to S transition in these
cells39. This suggests an inability of BCCIP to act in the DNA damage response and allow for
cell survival despite genetic instability in an HCC model.
In the cell cycle, BCCIP is an upstream regulator of the p53/p21 pathway of G1/S checkpoint
inhibition. BCCIPα acts as an upstream regulator of p53 by inducing p53 upregulation, which
subsequently increases p21 expression. In a human fibrosarcoma cell line, downregulation of
BCCIPα (RNAi-BCCIPα) impairs the G1/S checkpoint. Furthermore, ionizing radiation of the
RNAi-BCCIPα cell line with γ-rays at 10 Gy results in hastened progression through G1 and S
phases, while cell lines with normal basal expression of BCCIPα are blocked in G1.
Downregulation of p21 at the protein and mRNA levels in RNAi-BCCIPα cell line indicates
BCCIPα downregulation may lead to a lack of CDK2 inhibition in response to DNA damage40.
Recently, BCCIP has also been identified as a regulator of mitotic spindle integrity through the
C-terminus of BCCIPb localizing to spindle poles and both of its isoforms interacting with
dynein and dynactin; however, this function appears to be independent of its function in the
DNA-damage-response41.
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There is strong evidence suggesting BCCIP’s role in the HRR pathway. Radiation-induced
RAD51 foci colocalize with BCCIP in HRR. BCCIP and BRCA2 foci also co-localize in the
nucleus in an ionizing-radiation-independent manner, although there is no increase in BCCIP
foci in response to ionizing radiation. RAD51 foci co-localization with BCCIP occurs in a dosedependent manner of ionizing radiation. This suggests RAD51 foci co-localization, but not
BRCA2 foci co-localization, with BCCIP is involved in the DNA damage response in response
to ionizing radiation. Subsequent downregulation of BCCIP results in decreased formation of
RAD51 and BRCA2 foci42. Furthermore, BCCIP suppression increases spontaneous singlestranded and double-stranded DNA breaks in the absence of ionizing radiation43.
There is some preliminary research on the interaction between AEG-1 and BCCIP. In prostate
tumor cells, co-transfection of AEG-1 and BCCIPα in a yeast two-hybrid system demonstrate a
decrease in BCCIPα protein levels, and overexpression of AEG-1 induces proteasomal
degradation of BCCIPα. Proteasomal-mediated-downregulation of BCCIPα protein levels was
shown to depend on presence of the intact NH2-terminal domain of AEG-1, as demonstrated by
flag-tagged constructs with sequence deletions of AEG-144. However, it is unknown if BCCIPα
directly binds the NH2-terminal domain of AEG-1, or if BCCIPα degradation is a consequence
of downstream activity mediated by the amino terminus binding to other signaling molecules.
Due to the role of BCCIPα in the DNA damage response, and due to its interaction with AEG-1,
further studies delineating the potential role of AEG-1 in the DNA damage response can help us
better understand how HCC cells are able to overpass cell cycle checkpoints and continue
replicating their genomes despite exogenous DNA damage. Therefore, this may clue us into a
mechanism of radioresistance that occurs in HCC.

12

CHAPTER 2
MATERIALS AND METHODS
Generation of AEG-1 knockout (KO) cell lines
The DihXY cell line is a diethylnitrosamine-induced HCC mouse hepatic cell line. The cell line
was generously provided by Dr. Michael Karin's laboratory.
The QGY-7703 cell line was derived from a 30 year-old female human patient with aggressive
HCC. QGY-7703 cells also express AEG-1 at very high levels11. The cell line was obtained from
Fudan University, Shanghai, China.
The HuH7 cell line is a human-derived, well-differentiated hepatic cell line that was originally
obtained from a 57 year-old male with HCC. The cell line was generously provided by Dr. Paul
Dent’s laboratory.
AEG-1 knockout was attained in each of the above cell lines using the Crispr/Cas9 system. The
cloning vector was obtained from GeneCopoeia. The sgRNA targeted MTDH at the sequence
GACTTCAACAGTCCGCCCATT. The vector contained either puromycin or ampicillin
resistance genes with a selective mCherry marker. Cells were pulsed using the Gene Pulser Xcell
unit and then seeded at a density of 5 x 106 in 6-well plates. Single clones were isolated and
expanded using FACS-sorting for mCherry positive cells. For the DihXY cell line, a single
AEG-1 knockout clone (DihXY-A8) was used for subsequent studies. For the QGY-7703 cell
line, an AEG-1 knockout clone (QGY-A3), a partial knockout clone (QGY-A7) and a negative
clone (QGY-A26) were used for subsequent studies. For the HuH7 cell line, two knockout cell
lines (HuH7-A1 and HuH7-A6) and two negative cell lines (HuH7-A5 and HuH7-A12) were
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used for initial characterization of the cell lines. The HuH7-A6 and HuH7-A12 cell lines were
subsequently selected for radiation studies.
Cell culture conditions
HuH7 and QGY-7703 cell lines were grown in Dulbecco’s Modified Eagle Media (DMEM)
containing 10% (v/v) fetal bovine serum (FBS), 1% penicillin/streptomycin (PenStrep), and
.025% ciprofloxacin. DihXY cell line was grown in DMEM containing 20% FBS, 1% PenStrep,
.025% ciprofloxacin; and containing 0.12g phenobarbital, 20μL mouse epidermal growth factor
(0.5μg/μL solution), 0.005g hydrocortisone, and 0.5mL insulin per 500mL of media. All cell
lines were tested for mycoplasma-free status using a Mycoplasma Detection Kit (Thermo Fisher
Scientific). Cell lines were used for a maximum of 10 passages, and maintained at 37oC in a
humidified atmosphere containing 5% CO2.
Radiation treatment
For cells treated with radiation, they were subjected to ionizing radiation at a dose rate of 1-2
Gy/minute. DihXY cells were treated with 2.5, 5.0, and 10.0Gy; while QGY-7703 and HuH7
cells were treated at 2.5 and 10Gy.
Colony formation assay
500 cells were plated in 6cm dishes in triplicates per condition. For cells treated with ionizing
radiation or sorafenib, cells were plated at least 6 hours prior to treatment in order to allow cells
to adhere. Media was replaced every 4 to 5 days. 13 days after plating, cells were fixed with 10%
formaldehyde, gently rinsed with DI water and then incubated with a 25% working Giemsa
solution. After 1-hour incubation in stain, cells were rinsed thrice gently with DI water.
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MTT assay
2000 cells per well were seeded in 96-well plates and incubated in a 10% (3-(4,5Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) solution for 4 hours at either
24, 48, 72 hours, or at 48, 96, 144 hours post-seeding. Following incubation in MTT, 10%
sodium dodecyl sulfate (SDS) solution was added to cells. After incubating cells overnight,
absorbance was measured at 600nm using a GloMax microplate reader. For cells that received
sorafenib treatment, cells were seeded at the above density and allowed to adhere for 6 hours
prior to sorafenib treatment. For irradiated cells, cells were first plated in 6cm dishes and then
trypsinized and seeded in the 96-well plate following radiation.
Flow cytometry
To assess cell cycle progression in untreated QGY-7703, HuH7, and DihXYXY cells, cells were
synchronized using a double thymidine block to accumulate cells at the G1/S border and
subsequently released into S-phase. Thymidine was purchased from Sigma-Aldrich (catalog #
T1895). Cells were plated at a density of 2.5 x 105 cells in 10cm dishes. 200mM thymidine
solution was added to cell culture media to a final concentration of 2mM. Cells were first
blocked for 18 hours; then released with fresh DMEM for 9 hours; and blocked a second time for
17 hours. Following release with fresh DMEM from the second block, cells then fixed with cold
70% EtOH, treated with 100μg/mL RNase (purchased from Invitrogen) and stained with 1.0
mg/mL propidium iodide solution (purchased from Sigma Aldrich, catalog #P4864) overnight at
4oC prior to data acquisition.
For DihXY cells treated with radiation, cells were plated at a density of 2.5 x 105 in 10cm dishes
at least 6 hours prior to treatment. For FACS collection, cells were fixed with cold 70% EtOH,
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treated with 100μg/mL RNase and stained with propidium iodide overnight at 4oC prior to data
acquisition.
For QGY-7703 and HuH7 treated with radiation, cells were plated at a density of 2.5 x 105 cells
in 10cm dishes at least 6 hours prior to treatment. The FITC BrdU Flow Kit (purchased from BD
Biosciences, catalog #559619) was used to double-stain samples with 7-AAD and BrdU.
Following radiation, HuH7 cells were pulsed with 1mM BrdU solution for 30 minutes (BrdU
incubation time was optimized in untreated HuH7 cells). Cells were then washed with DPBS and
fresh media was added. Cells were fixed and stained with anti-BrdU and 7-AAD per the staining
kit protocol. Briefly, cells were trypsinized, treated with Cytofix/Cytoperm Buffer for 20 minutes
at room temperature, treated with Cytoperm Permeabilization Buffer Plus for 10 minutes on ice,
and treated a second time with Cytofix/Cytoperm Buffer for 5 minutes on ice. Cells were then
treated with DNase for 1 hour at 37oC, stained with anti-BrdU for 20 minutes, and then stained
with 7-AAD overnight at 4oC prior to data acquisition. Negative controls were cells pulsed with
BrdU and either 1) stained with neither anti-BrdU nor 7-AAD; 2) stained with anti-BrdU; or 3)
stained with 7-AAD.
For QGY-7703 cells, cells were collected at 30 minutes post-radiation or post-double-thymidineblock and subsequently every 4 hours for 12 hours. For HuH7 cells, cells were collected at 30
minutes and subsequently every 6 hours for 48 hours. For cells, cells were collected at 30
minutes and subsequently every 4 hours for 24 hours.
BD FACSCanto™ II Analyzer and FACSDIVA software at the VCU Flow Cytometry Shared
Resource Core was utilized to acquire and analyze data. Flow cytometry data was analyzed using
FlowJo data analysis software.
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Immunohistochemistry
Immunohistochemistry was used to analyze BCCIP expression in previously obtained Cre/lox
AEG-1 knockout, and wiltype AEG-1, hepatic tissues of C57BL/6 mice45. Briefly, paraffinembedded tissues were fixed to glass slides and incubated at 60 oC for one hour. Slides were then
incubated in xylene twice to de-paraffin the tissues. 100%, 90%, 80%, and 70% EtOH were used
to rehydrate the tissues. Subsequently, tissues were incubated in water and PBS for 5 minutes
each. Antigen retrieval buffer was applied to the tissues for 10 minutes in microwave, and then
rinsed with PBS. 2% hydrogen peroxide was used to quench endogenous hydrogen peroxidase
for 20 minutes, and then rinsed with PBS. Slides were blocked in 5% goat serum for 1 hour at
room temperature. Slides were incubated in primary antibodies (AEG-1 and BCCIP) overnight at
4oC. Slides were rinsed with PBST thrice for 5 minutes, and then incubated in biotinylated
secondary antibody for 1 hour at room temperature. Following secondary antibody incubation,
slides were washed thrice for 5 minutes, and then incubated in ABC reagent for 30 minutes at
room temperature. Slides were again rinsed thrice with PBST for 5 minutes. Slides were
incubated in DAB substrate for 1-5 minutes, then rinsed in water and incubated in hematoxylin
for 20 seconds. After rinsing with water, tissues were dehydrated using gradient EtOH, cleaned
with xylene, and slides were mounted with permount.
Immunofluorescence
Cells were seeded at a density of 2.5 x 104 cells/mL in Millicell EZ slides (Millipore). For cells
treated with ionizing radiation, cells were allowed at least 6 hours to adhere prior to treatment.
To fix cells, 4% paraformaldehyde was used and then washed thrice with DPBS. Cells were then
permeabilized with 0.1% triton solution and washed thrice with DPBS. A 1% bovine serum
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albumin, 10% goat serum in 10x PBS solution was used to block cells for 2 hours at room
temperature. Following blocking, cells were treated with primary antibody overnight at 4oC.
Cells were washed with DPBS and then incubated with a 1:400 dilution of fluorochrome
conjugated secondary antibodies in blocking buffer for 1 hour at room temperature. Cells were
then washed with DPBS and mounted with DAPI. Negative controls used in this assay were cells
incubated with primary antibody, but no secondary antibody. Antibodies used were BCCIP
(ProteinTech #16043-1-AP), γ-H2AX (Cell Signaling #9718) and AEG-1. Images were acquired
using a Zeiss LSM confocal microscopy at a magnification of 63x at the VCU Microscopy Core,
and quantified using ImageJ.
In vitro wound healing assay
2-well silicone inserts were purchased from Ibidi (catalog #80209) to assess cell migration. 70μL
of a 5 x 105 cells/mL suspension was added to each side of the well, one insert per well in 12well plates. Cells were allowed to adhere overnight. The insert was removed, which created a
500μM lesion, and fresh media was added to each well. The resulting lesion was imaged at 0, 24,
and 48 hours following removal of the insert. Images were obtained with at 4x and 10x
magnification. Lesion sizes at 10x magnification at each time point were quantified using the
MetaVi Labs online automated cellular analysis system.
Invasion assay
BioCoat™ Matrigel® Invasion Chambers were purchased from Corning. Serum-free DMEM
containing 0% FBS was used to rehydrate the inserts for 2 hours at 37oC and 5% CO2. 750μL of
DMEM containing 10% FBS was added to each well in a 24-well plate. Inserts were placed in
each well, and 2.5 x 104 cells suspended in 500μL serum-free DMEM were added to each insert.
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The cells were incubated for 22 hours at 37oC and 5% CO2. Following incubation, DMEMmoistened cotton swabs were used to gently remove non-invasive cells from the inserts. The
inserts were then fixed and stained with a Diff-Quik staining kit. Images of the invading cells
were taken at 10x magnification. The number of invading cells per field were counted manually.
Western blotting
Cells to be collected for total protein lysate were seeded at a density of 1.0 x 106 in a 6cm dish.
Cells were then washed with DPBS twice and treated with 1.5% n-dodecyl-D-maltoside (DDM)
lysis buffer containing PhosStop Easypack phosphatase inhibitor cocktail tablets (Roche) and
cOmplete Mini protease inhibitor cocktail tablets (Roche). After lysis, cells were centrifuged at
15000 RPM for 15 minutes. Supernatant was carefully removed and protein concentration was
measured using Bradford assay. 20μg to 40μg of protein lysate was resolved in 8 to 12% SDSPAGE and then transferred on nitrocellulose membranes. Following transfer, cells were blocked
in 5% nonfat milk in TBST solution for 1 hour. For primary antibodies to be incubated in bovine
serum albumin, membranes were washed 3 x 5 minutes with TBST prior to adding antibody. All
membranes were incubated overnight at 4oC. Prior to secondary antibody incubation, cells were
washed 3 x10 minutes with TBST. Secondary antibodies were applied for 1 hour at room
temperature. Membranes were washed again 3 x 10 minutes with TBST. Chemiluminescence
detection reagents were applied to membranes and images of the proteins were obtained on
autoradiography films. EF1α or GAPDH were used as internal controls. Western blot images
were quantified using ImageJ.
List of antibodies used:
•

•

Cyclin D1 Cell Signaling #2978
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BCCIP ProteinTech 16043-1-AP

•

p21 Cell Signaling #2947

•

p53 Cell Signaling #2527

•

Phospho-ATR (Ser428) Cell

•

gH2AX (Ser139) Cell Signaling

Signaling #2853
•

#9718
•

Phospho-BRCA1 (Ser1524) Cell
Signaling #9009

•

GAPDH Santa-Cruz sc-166545

•

Phospho-Chk2 (Thr68) Cell

Phospho-p53 (Ser15) Cell Signaling
#9286

•

Phospho-ATM (Ser1981) Cell
Signaling #5883

Signaling #2197

•

ATM Cell Signaling #2873

Phospho-Chk1 (Ser345) Cell

•

ATR Cell Signaling #13934

Signaling #2348

•

AEG-1

•

Chk1 Cell Signaling #2360

•

EF1α Millipore 05-235

•

Chk2 Cell Signaling #2662

•

Cyclin E Santa-Cruz sc-481

•

Statistical analyses
Significance of results was tested using student paired T-test with two-tailed hypothesis.
Statistical significance for all data was considered to be a P value of <0.05.
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CHAPTER 3
RESULTS
Knockout of AEG-1 using Crispr-Cas9 reduces cell proliferation in HCC cells
AEG-1 knockout was previously achieved in the DihXY cell line46, and for this study, was
successfully replicated in the QGY-7703 and HuH7 cell lines using the Crispr-Cas9 vector. A
single knockout and negative (wildtype AEG-1) clone were selected from the HuH7 and QGY7703 cell lines, along with a partial knockout clone in the QGY-7703 cell line. A negative clone
was not available in the DihXY cell line, so the parental cell line was used for AEG-1 WT
characterization. AEG-1 expression was confirmed in the knockout and negative HuH7 and
QGY-7703 cell lines using western blotting (Fig. 1A). The AEG-1 WT and KO cell lines were
initially characterized for cell survival and cell viability. Significantly fewer colonies formed in
the AEG-1 KO cell line compared to the AEG-1 WT and partial KO cell lines in the QGY-7703
cell line (Fig. 1B, P-values 0.0425 and 0.0163, respectively). However, there was no significant
difference in colony formation in the HuH7 cell lines (Fig. 1E). In the MTT assay, QGY-7703
AEG-1 KO cells showed significantly reduced proliferation compared to AEG-1 WT cells at 24-,
48-, and 72-hour time-points (P-values 0.00014, <0.00001, and 0.00024, respectively). When the
percent cell viability of QGY-7703 AEG-1 KO cells was normalized against AEG-1 WT cells,
the AEG-1 KO cells only proliferated up to 78% that of the AEG-1 WT cell line, and did not
show exponential growth (Fig. 1C). On the other hand, the HuH7 AEG-1 KO cell line had
increased cell viability at all time-points in the MTT assay (Fig. 1D). When the percent cell
viability of HuH7 AEG-1 WT cells were normalized against AEG-1 KO cells, the WT cells
showed a sharp increase in proliferation after 3 days of incubation. The WT cells continued to
increase until they reached 82.5% cell viability of the KO cells after 8 days of incubation.
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Knockout of AEG-1 results in decelerated cell cycle progression
After observing the phenotypic effect of AEG-1 knockout in cell proliferation, we sought to
characterize the cell cycle profiles of AEG-1 WT and KO cell lines. Although all cell lines
demonstrated marked cell cycle acceleration (Fig. 2A-D), this was more apparent in the QGY7703 WT cells compared to the DihXY cells or HuH7 cells.
Three independent cell cycle experiments were performed on untreated, QGY-7703 cells that
were synchronized into the G1/S boundary using a double thymidine block, and subsequently
stained with either PI or 7-AAD. For each experiment, 20,000 cellular events were recorded
during FACS data acquisition. Cells were gated into G1/G0, S, and G2/M and a percentage of
cells in each phase was calculated. These percentages from each independent experiment were
averaged and standard deviation error was calculated to determine the reliability of our methods
(Fig. 2A). The figure shows that we were able to consistently synchronize the cells into the G1/S
boundary and release into S-phase. Furthermore, our results also show that the QGY-7703 cell
lines maintain a routine pattern of accumulating in G0/G1 after 12 hours, with the AEG-1 WT
cells proceeding more rapidly than the AEG-1 KO cells. Although the error bars are not tight, we
argue that this is because the mean and standard deviation were calculated from three datapoints, while each of these data-points contained at least 20,000 cellular events. Therefore, we
can reliably use this method of analyzing cell cycle progression for our project.
DihXY AEG-1 WT and KO cells were released into S-phase (42.3% and 51.2%, respectively)
following double-thymidine block (Fig. 2B). Both KO (55%) and WT (53.1%) cells are
maximally in G2/M after 4 hours and complete a round of replication after 8 hours. After 24
hours, KO (72.4%) and WT (47.5%) cells are maximally in G1/G0 once more, completing a
second round of replication. However, at 24 hours, WT cells are entering S- (21.7%) and G2/M
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(30.7%) phases, while KO cells remain accumulated in G1/G0 (S-phase cells 14.5%, G2/M cells
13.2%), indicating the WT cells are entering a third round of replication more rapidly than KO
cells.
Following release of QGY-7703 cells from a double-thymidine block, AEG-1 WT and KO cells
were accumulated in S-phase (69.6% and 69.3%, respectively; Fig. 2C). After 4 hours, WT cells
accumulated in G1/G0 (75.4%), while KO cells were still cycling in S (49.5%) and G2/M (39%),
indicating WT cells had successfully completed replication. KO cells do not accumulate in
G1/G0 (70.3%) until 12 hours post-release, at which time WT cells accumulate in G1/G0 again
(81%) and have completed a second cycle of replication.
HuH7 AEG-1 WT and KO cells were released into S-phase (59.4% and 73.2%, respectively)
after a double-thymidine block (Fig. 2D). Both KO and WT cells complete their first round of
replication after 18 hours (data not shown). After 24 hours, WT cells appear to complete a
second cycle of replication, at which point they accumulate in G1/G0 (54.1%). At 12-, 24-, and
36-hours post-release, HuH7 AEG-1 WT cells are accumulated in G1/G0 to a higher percent
compared to HuH7 AEG-1 KO cells.
Knockout of AEG-1 reduces migration and invasion in HCC cells
To further characterize the effect of AEG-1 knockout in QGY-7703 cells, the Crispr/Cas9
generated cell lines were assessed for their invasive and migratory capabilities. As previously
described, AEG-1 has been well-studied in its role in upregulating various cell invasion and
migration pathways, including NfkB, MMP2, and MMP9 signaling. Invasion assay using QGY7703 cells (Fig. 3A, top) showed a significantly increased number of invading cells per field in
both the partial KO and WT AEG-1 cells, compared to the KO cells (P-values 0.00600 and
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0.00596, respectively). Similarly, HuH7 cells assayed for invasive capacity (Fig. 3A, bottom)
showed a significantly reduced number of invading cells in the AEG-1 KO cell line compared to
AEG-1 WT cells (P-value 0.00068). In the wound healing assay (Fig. 3B, top), QGY-7703
AEG-1 KO cells showed significantly reduced cell migration within 24 hours of creating the
lesion (P-value 0.03968). However, both cell lines equally migrated after 48 hours. There was no
significant difference in the initial lesion size (P-value 0.26529).
In the HuH7 cell lines, A6 (AEG-1 KO) cells showed significantly reduced cell migration
compared to the A5 and A12 (AEG-1 WT) cells after 48 hours (P-values 0.01760 and 0.02136,
respectively; Fig. 3B, bottom). The initial lesion size between the A6 and A5/A12 cell lines were
not significantly different (P-values 0.45298 and 0.89823, respectively).
Knockout of AEG-1 sensitizes HCC cells to low-dose IR
In QGY-7703 and HuH7 cell lines, AEG-1 KO cells were significantly sensitized to radiation
treatment at 2.5 Gy (Fig. 4A and 4C, respectively). In QGY-7703 cells, P-value was 0.00633; in
HuH7 cells, P-value was 0.02871. Although DihXY AEG-1 WT cells showed marked resistance
to IR at 2.5 Gy, the results were not significant (Fig. 4B, P-value 0.05602).
Negative and positive regulators of the G1/S transition are upregulated in AEG-1 WT QGY-7703
cells following low-dose IR
After observing sensitization of AEG-1 knockout cells to ionizing radiation, and the differences
in cell cycle progression in the cell lines following IR, we decided to study protein expression of
signaling molecules involved in the G1/S transition in both untreated cells and cells treated with
low-dose IR (2.5 Gy). In QGY-7703 cells treated with 2.5 Gy, there was a 16.7% decrease from
G1/G0 in WT cells between 4 to 8 hours, while only 4.8% decrease in KO cells. At 8 and 12
hours, KO cells are 59.1% and 58.8% in S-phase, respectively; while WT cells are 30.8% and
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48% in S-phase, respectively (Fig. 5B). This correlates with a decrease in cyclin D1 expression
in WT cells at 8 and 12 hours compared to KO cells after IR (Fig. 6C). p-p53 expression was
consistently upregulated in WT cells at all time-points following IR at 2.5 Gy. Similarly, p21
expression was upregulated in IR-treated WT cells at 8 hours. On the other hand, in KO cells
treated with IR, p-p53 expression decreased at 30 minutes and 4 hours, while it remained
unchanged at 8 and 12 hours. Interestingly, p21 expression was downregulated in IR-treated KO
cells at 8 and 12 hours when compared to untreated KO cells (Fig. 6A). Total p53 expression in
untreated QGY-7703 cells was greater in the AEG-1 WT cell line than in the KO cell line at 8
and 12 hours (Fig. 6B). This observation correlates with greater p-p53 signaling at 8 and 12
hours. When revisiting the cell cycle data, we observe that the untreated QGY-7703 AEG-1 KO
and WT cells are maximally in G2/M at 8 hours, and re-entering G0/G1 at 12 hours postthymidine release (Fig. 2C), indicating p53 expression is transcriptionally activated when these
cells are minimally in S-phase. Unexpectedly, bands for p53 were not visible in either WT or KO
cells when irradiated at 2.5Gy.
Cyclin D1 expression was increased in UT AEG-1 WT cells compared to AEG-1 KO cells;
however, following IR at 2.5 Gy, AEG-1 KO cells showed increased cyclin D1 expression
compared to AEG-1 WT cells (Fig. 6C). In both AEG-1 WT and KO cells, cyclin E expression
was consistently upregulated after treatment at 2.5 Gy and 10Gy (Fig. 6C). At 30 minutes post2.5 Gy, cyclin E expression triples in KO cells, compared to untreated cells at the same timepoint; while expression in WT cells increases approximately 1.7-fold. At 4 hours post-2.5 Gy,
cyclin E expression doubles in both KO and WT cells when compared to untreated cells at the
same time-point; however, at 10Gy, expression in KO cells nearly triples, while in WT cells it
only increases by about 2.5-fold. Cyclin E expression is reported to be highest during the G1/S
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transition47; however, in both IR-treated KO and WT cells, cyclin E expression peaks at 8 and 12
hours, while their cell cycle profiles show they are in majority S- or G2/M phase (Fig. 5B).
Positive regulators of the G1/S transition are upregulated in AEG-1 WT HuH7 cells following IR
In the irradiated HuH7 cells, both KO and WT cells had similar cell cycle profiles initially after
radiation (KO = 49.6% and WT = 50.8% in G1/G0; Fig. 5A). At 12 and 24-hours post-2.5 Gy,
there was a greater percentage of KO cells in G1/G0 than WT. At 24 hours, 24.9% WT cells
were in G2/M, compared to only 18.2% of KO cells. After 12 hours, more WT cells have cycled
into S (30.6%) and G2/M (34.8%), compared to KO cells (27.6% in S, 29.3% in G2/M). When
analyzing protein expression of cell cycle regulators, we found that HuH7 AEG-1 WT cells
showed increased expression of cyclin E initially (30 minutes) after thymidine release (Fig. 7B).
Afterwards, cyclin E expression remained consistently higher in untreated KO cells when
compared against untreated WT cells. This conflicts with the pattern of cyclin E expression in
irradiated QGY-7703 cells (Fig. 6C), which showed increased expression in the untreated WT
cells at all time-points except at 8 hours. In the HuH7 cells treated with 2.5Gy, cyclin E was
initially upregulated in KO cells , while it was downregulated in the WT cells, when compared
against their untreated counterparts. After 12 hours, cyclin E was downregulated in both WT and
KO cells, although it was decreased approximately 50% in KO cells and 80% in WT cells. At 24
hours following IR, cyclin E expression remained downregulated in KO cells, while its
expression was increased in WT cells, compared to their untreated counterparts (Fig. 7B). This
replicates a similar observation of cyclin E upregulation in irradiated QGY-7703 AEG-1 WT
cells, although the QGY-7703 cells showed a more profound and consistent pattern of cyclin E
upregulation (Fig. 6C).
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Similar to QGY-7703 cells, p21 expression peaked in both HuH7 AEG-1 WT and KO cells at
the last time-point following thymidine release (Fig. 7A), which correlates with WT cells
accumulating in G1/G0 (Fig. 2D), but does not corroborate with our observation that KO cells
accumulate in S-phase at that time-point (Fig. 2D). Unlike QGY-7703 cells, HuH7 AEG-1 WT
cells did not appear to upregulate p21 expression to a higher degree than KO cells following IR
at 2.5Gy (Fig. 7A). In the irradiated HuH7 cells, p21 expression appeared to decrease in AEG-1
KO cells at the 12 and 36 hour time-points, which correlate with a lack of robust G1/G0
accumulation at these time-points (Fig. 5A). On the other hand, irradiated AEG-1 WT cells did
not show a change in p21 expression at the 12 hour time-point, but p21 expression was
downregulated at 24 and 36 hours post-IR when compared to its untreated counterparts.
AEG-1 KO results in delayed DSB signaling compared to AEG-1 WT cells following low-dose IR
In the QGY-7703 cell lines, protein expression of the phosphorylated forms of the DNA doublestranded break sensors ATR and ATM were more strongly upregulated in AEG-1 WT cells at 30
minutes post-IR at 2.5Gy when compared to irradiated AEG-1 KO cells (Fig. 8A and 8C). This
pattern of expression was consistent for p-ATR at all time-points following IR, but p-ATM
expression had stronger expression in the AEG-1 KO cells starting at 8 hours post-IR at 2.5Gy.
Although quantification of gH2AX expression against internal control showed higher expression
in irradiated WT cells than irradiated KO cells at 30 minutes (Fig. 8C), the western blot images
and IF imaging stained with the same gH2AX antibody (Fig. 11B-C) demonstrated increased
signal in KO cells than in WT cells at this time-points. Notably, p-ATR – which has a stronger
role in sensing single-stranded DNA breaks and stalled replication forks (reviewed in Haynes,
Murai, and Lee, 201847) – was markedly upregulated in both untreated and IR-treated AEG-1
WT cells at all time-points, with the exception of 8 and 12 hours post-IR at 10 Gy (Fig. 8A, C).
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p-ATR expression peaks in both WT and KO cells 4 hours post-IR at 2.5Gy; 8 hours following
IR at 2.5Gy, WT cells are accumulated majority in G2/M (37.2%), while KO cells are
accumulated in S-phase (59.1%). Prior to this time-point KO and WT cells show similar cell
cycle profiles, indicating KO cells are arrested in S-phase at 8 hours while WT cells have
continued progressing into G2/M (Fig. 5B).
When probing for the downstream checkpoint proteins, p-Chk1 and p-Chk2, in the QGY-7703
cells (Fig. 9) there appeared to be an upregulation of p-Chk2 in both IR-treated cell lines at all
time-points, compared to the untreated cell lines. In the WT cells, p-Chk2 expression had more
prominent upregulation from 30 minutes to 8 hours post-IR, while expression was increased in
KO cells at 12 hours post-IR (Fig. 9A, right, and Fig. 9B, right). There did not appear to be a
significant difference in p-Chk1 expression between the two IR-treated cell lines at 30 minutes
and 4 hours, however, at 8 and 12 hours post-IR, there was increased signaling in KO cells
compared to WT cells (Fig. 9A, left, and Fig. 9B, left).
As for HuH7 cells, p-ATM signaling was initially increased in WT AEG-1 cells following IR at
2.5Gy, but at 12 and 24 hours, KO cells demonstrated increased expression compared to WT
cells (Fig. 10A), which is similar to what was observed in QGY-7703 AEG-1 KO cells at 8 and
12 hours post-IR. Although p-BRCA1 expression was greater in irradiated WT cells compared to
KO cells at 24 hours post-IR, at 36 hours irradiated KO cells had markedly increased signaling
compared to WT (Fig. 10C). In fact, p-BRCA1 expression in KO and WT cells appeared to be
downregulated at 30 minutes, 12 and 24 hours post-IR when compared to untreated cells, and
this downregulation persisted in KO cells until 36 hours, at which point its expression was
upregulated compared to untreated cells. Interestingly, p-BRCA1 expression in WT cells never
increased in the irradiated cells when compared against untreated cells at all time-points.
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Analysis of p-ATR did not show a remarkable difference between the IR-treated WT and KO
clones (Fig. 10B) at 30 minutes and 12 hour post-treatment. However, at 24 hours, the WT cells
had increased expression in both untreated and irradiated circumstances. At 36 hours, p-ATR
was upregulated in KO irradiated cells compared to untreated cells, while it was downregulated
in irradiated WT cells at this time-point.
The downstream signaling kinases p-Chk1 and p-Chk2 in HuH7 cells did not show a similar
pattern of expression as in the QGY-7703 cells. p-Chk1 expression (Fig. 10E) was increased in
irradiated WT cells compared to KO cells at all time-points, although p-Chk1 in the untreated
WT cells was also higher than untreated KO cells at 12, 24, and 36 hours post-thymidine release.
p-Chk2 expression (Fig. 10D) on the other hand was greater in irradiated KO cells than WT cells
at 30 minutes, 12 hours, and 36 hours. However, compared to untreated cells, p-Chk2 expression
was upregulated at 30 minutes and 24 hours in irradiated WT and KO clones, which we did not
observe in p-Chk1 expression.
BCCIP is upregulated in AEG-1 KO mice liver tissue, but not in an in vitro system
Due to evidence indicating BCCIP downregulation induced by AEG-1 overexpression in prostate
tumor cells (Ash et al. 2008), we sought to replicate this observation in HCC cells. Although
immunohistochemistry staining of BCCIP in mouse hepatic tissues showed upregulation of
BCCIP in the AEG-1 KO samples (Fig. 12A), we were unable to replicate similar results in
immunofluorescence staining of DihXY or QGY-7703 AEG-1 KO cells (Fig. 12C). Western blot
analysis for BCCIP showed a band approximately 45 kDa that appeared to be downregulated in
the DihXY AEG-1 WT clone; however, this band was not observed in the mouse hepatic
samples (Fig. 12B). Bands closer to the theoretical size of BCCIP, approximately 36 kDa, were
downregulated in two of the mouse hepatic samples, but were unchanged in the DihXY samples.
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In HuH7 cells released from a double thymidine block, there did not appear to be a marked
difference in BCCIP expression between the untreated cell lines, although expression was
increased in KO cells compared to WT cells to some extent at 30 minutes, 12 hours, and 36
hours following release (Fig. 13B).
BCCIP is upregulated in HCC cells following low-dose IR
Because BCCIP is involved in the HRR pathway, we reasoned that inducing DSB’s via IR could
clue us in to why we were not observing an upregulation of BCCIP in the AEG-1 KO cells. We
hypothesized that BCCIP upregulation in AEG-1 WT cells could be an underlying factor in their
resistance to radiation treatment. Protein expression of BCCIP in QGY-7703 cells (Fig. 13A)
corroborated our hypothesis that AEG-1 WT HCC cells upregulate BCCIP and are resistant to
IR. Untreated WT cells and cells treated with 2.5 Gy demonstrated higher expression of BCCIP
than KO cells at 0, 4, and 8 hours post-thymidine-release or post-IR; furthermore, BCCIP was
not upregulated in KO cells at 8 hours post-IR. However, in UT KO cells was BCCIP expression
was higher than that of WT cells. Interestingly, immunofluorescence of BCCIP (Fig. 13C) was
steadily increased in AEG-1 KO cells at all time-points following IR at 2.5 Gy. The expression
profile of BCCIP in QGY-7703 WT and KO cells is therefore parallel to p-p53 and p21
expression in response to low-dose IR.
Although BCCIP upregulation in response to IR was confirmed through both IF and western blot
analysis in the QGY-7703 cell lines, this was not observed in the HuH7 cell lines. Protein
expression of BCCIP in HuH7 AEG-1 KO cells was downregulated to a greater extent than WT
cells at 30 minutes and 24 hours post-treatment with 2.5Gy IR (Fig. 13B). Interestingly, BCCIP
expression was increased in AEG-1 KO cells at 12 and 36 hours post-IR when compared against
IR-treated WT cells. These results conflict with both the observation of BCCIP upregulation in
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IR-treated compared to untreated cells,, and BCCIP upregulation in WT compared to KO cells,
in the QGY-7703 cell lines.
AEG-1 expression in HCC cells is upregulated following ionizing radiation
An unexpected result we observed in the radiation studies was increased AEG-1 signaling in
QGY-7703 cells treated at 2.5Gy, as indicated by both western blotting (Fig. 8D, Fig. 13A) and
immunofluorescence (Fig. 13C). This increase in signaling was observed by western blotting at
30 minutes until 8 hours post-treatment, but not at 12 hours (data not shown). Meanwhile, AEG1 signaling was markedly increased in the IF images at 30 minutes post-treatment. However, this
increase in AEG-1 signaling was not observed in the HuH7 AEG-1 WT cells (Fig. 10F).
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8

Figure 1 Knockout of AEG-1 reduces cell survival and viability in control, untreated
QGY-7703 cells, but not HuH7 cells. (A) Western blot images demonstrate expression
status of AEG-1 in the QGY-7703 clones and HuH7 clones. GAPDH was used as an internal
control. QGY-7703 cells were assessed for cell survival in (B) colony formation assay and
cell viability in (C) MTT assay. Cell viability – measured by the average absorbance at
600nm – of QGY-7703 AEG-1 KO and partial KO cells were normalized against AEG-1
WT cells. (D) Cell viability of HuH7 cells using the MTT assay, shown by the average
absorbance of AEG-1 WT cells normalized against AEG-1 KO cells. Although KO cells had
increased proliferation at all time-points, WT cells showed a sharp increase in cell
proliferation after two days of incubation. (E) Colony formation of HuH7 cells showed there
was no significant difference in cell survival between the AEG-1 WT and KO cell lines.
* P<0.05.
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Figure 2 AEG-1 knockout slows cell cycle progression in HCC cells. Cells were treated with a
double thymidine block, released into S-phase, and then collected for FACS cell cycle analysis at
various time-points. Graphs display the percentage of cells in the total population (>10,000
events per sample) that were in G1/G0, S, or G2/M based on nuclear staining profile. (A)
Averaged cell cycle data of three independent experiments using QGY-7703 cells stained with
either PI or 7-AAD. (B) DihXY cells stained with PI. After 24 hours, KO cells are maximally in
G1/G0 while WT cells are continuing progression into S and G2/M. (C) QGY-7703 cells stained
with 7-AAD. 4 hours after release, AEG-1 WT cells have returned to G1, while AEG-1 KO cells
are still cycling through G2/M. AEG-1 WT cells completes two cycles after 12 hours, while
AEG-1 KO completes 1 cycle. (D) HuH7 cells stained with PI. At all time-points, there are
increased AEG-1 WT cells accumulated in G1/G0 compared to AEG-1 KO cells.

34

QGY-7703
*

45

100

40

90

35

80

30

*

25
20
15

*

70
60
50
40
30

10

20

5

10
0

0
AEG-1 KO (- AEG-1
/-)
partial KO
(+/-)

AEG-1 KO

AEG-1 WT
(+/+)

40

Percent migration

30
25
20
15
10
5
0
AEG-1 KO (-/-)

24 to 48 hours

100
90
80
70
60
50
40
30
20
10
0

*

A1 (AEG-1
KO)

AEG-1 WT (+/+)

A6 (AEG-1
KO)

0 to 24hr

(C)

AEG-1 WT
Total Migration

HuH7

*

35

AEG-1 partial KO

0 to 24 hours

HuH7
Average # of invading cells/field

QGY-7703

(B)

Percent migration

Average # of invading cells/field

(A)

(D)

0hr

AEG-1
KO (-/-)

AEG-1
partial KO
(+/-)
AEG-1
WT (+/+)

35

24hr

24 to 48hr

*

A5 (AEG-1
WT)

A12 (AEG-1
WT)

Total migration

48hr

(E)

(F)
0hr

24hr

48hr

AEG-1
KO (-/-)

AEG-1
WT (+/+)

Figure 3 Knockout of AEG-1 reduces in vitro wound healing and invasion in QGY-7703
and HuH7 cells. Matrigel invasion assay and wound healing assays were used to assess
invasive and migratory capacities, respectively, of QGY-7703 and HuH7 cell lines. (A) AEG1 WT and partial KO cells showed significantly increased invading cells per field compared to
AEG-1 KO cells in the QGY-7703 cell line (top). Similarly, AEG-1 KO in HuH7 cells
significantly reduced the average number of invading cells (bottom). (B) AEG-1 KO cells had
significantly reduced migration in the first 24 hours compared to AEG-1 WT cells in the
QGY-7703 cell line (top). In the HuH7 cell line, the A6 AEG-1 KO cell line had significantly
reduced total migration compared to both A5 and A12 AEG-1 WT cell lines (bottom). (C)
Representative images of invading cells per field from the QGY-7703 cell line. (D)
Representative images of QGY-7703 cell lines in the matrigel invasion assay at 0, 24, and 48
hours following generation of the wound. (E) Representative images of invading cells per
field from the HuH7 cell line. (F) Representative images of HuH7 A6 and A12 cell lines in the
matrigel invasion assay at 0, 24, and 48 hours following generation of the wound.
* P<0.05
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Figure 4 Knockout of AEG-1 sensitizes HCC cells to low-dose radiation treatment.
Colony formation assay was used to assess cell survival following ionizing radiation at
various doses. QGY-7703 cells (A) and DihXY cells (B) showed significantly reduced
survival in the KO cell line at 2.5 Gy. DihXY colony formation is shown as percent colony
formation against control. (C) HuH7 cell survival was significantly reduced in the KO cell
line following treatment at 2.5 Gy (left). Representative images of colonies in the WT and KO
cell lines (right). *P<0.05
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Figure 5 In HCC cells, low-dose ionizing radiation induces greater G2/M accumulation
in AEG-1 WT cells, while AEG-1 KO cells at later time-points. Cells were treated with
2.5 Gy [(A) and (B)], or 10 Gy [(C) and (D)] and collected at various time-points. QGY7703 and HuH7 cells were double-stained with anti-BrdU and 7-AAD. DihXY cells were
stained with PI. Graphs display the percentage of cells in the total population (>10,000
events per sample) that were in G1/G0, S, or G2/M based on nuclear staining profile. (A)
HuH7 cells treated at 2.5 Gy show increased G2/M accumulation at 12- and 24-hour timepoints in the AEG-1 WT cell line, while AEG-1 KO cells accumulate in G1/G0. (B) QGY7703 cells treated at 2.5 Gy show AEG-1 WT cells are maximally in G2/M at 8 hours, while
AEG-1 KO cells accumulate in S-phase at 8- and 12-hour time-points.
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Figure 6 Following low-dose IR of QGY-7703 AEG-1 WT cells, p-p53 and cyclin E protein
expression are upregulated, while p21 and cyclin D1 protein expression are downregulated.
QGY-7703 cells were collected for whole protein lysate following IR (2.5 and 10Gy) or release
from double thymidine block (UT) at 30 minutes, 4 hours, 8 hours, and 12 hours. Lysates were
then subjected to SDS-PAGE and probed for negative (A) and positive (C) regulators of the G1/S
transition. (A) Western blot images showing expression of p-p53 and p21 in QGY-7703 cells
(left) and quantification of expression relative to GAPDH (right). For p-p53, the lower band was
used for quantification due to its proximity to the theoretical size of p-p53. P-p53 expression was
increased in AEG-1 WT cells following IR at all time-points, while it was downregulated in
AEG-1 KO cells at 30 minutes and 4 hours after IR. Meanwhile, p21 expression was
downregulated in AEG-1 WT cells at all time-points following IR. In AEG-1 KO cells, p21
expression was initially upregulated following IR, but after 8 hours its expression was
downregulated. (B) Western blot images showing total p53 expression in QGY-7703 cell lines.
GAPDH was used as an internal control. (C) Western blot images showing expression of Cyclins
E and D1 (left) and quantification of expression of cyclin E relative to GAPDH (right). Cyclin E
expression was upregulated in both KO and WT AEG-1 cells following both doses of IR.
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Figure 7 After low-dose irradiation of HuH7 cells, cyclin E protein expression oscillates in
both AEG-1 WT and KO cells, while p21 and cyclin D1 expression is consistently
downregulated in both WT and KO cells. HuH7 cells were collected for whole protein lysate
following IR (2.5Gy) or release from double thymidine block (UT) at 30 minutes, 12 hours, 24
hours, and 36 hours. Lysates were then subjected to SDS-PAGE and probed for negative (A)
and positive (B-C) regulators of the G1/S transition. (A) Western blot images showing
expression of p21 (right) and quantification relative to EF1a. (B) Western blot images showing
expression of cyclin E (right) and quantification relative to GAPDH (left). (C) Western blot
images showing expression of cyclin D (right) and quantification relative to EF1a (left).
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Figure 8 Low-dose ionizing radiation induces strong, rapid DSB signaling in AEG-1
WT cells, while DSB signaling in AEG-1 KO cells begins at later time-points, in the
QGY-7703 cell line. QGY-7703 cells were collected for whole protein lysate following
ionizing radiation or release from double thymidine block at 30 minutes, 4 hours, 8 hours,
and 12 hours. Lysates were then subjected to SDS-PAGE and probed for various DNA
damage response markers. (A) Western blots showing total ATR and ATM (top) and pATM, p-ATR, and gH2AX expression (bottom). p-ATR and p-ATM signaling were initially
greater in AEG-1 WT cells at 30 minutes post-IR at 2.5Gy, while gH2AX signaling was
greater in irradiated AEG-1 KO cells at 30 minutes. (B) Western blot showing p-BRCA1
signaling was increased in AEG-1 KO cells following IR at 2.5 and 10 Gy compared to
AEG-1 WT cells. (C) Protein expression for p-ATR, p-ATM, p-BRCA1, and gH2AX were
quantified using ImageJ against their respective internal controls. (D) Representative blots
of internal controls. AEG-1 expression was consistent with KO and WT cell lines.
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Figure 9 p-Chk2, but not p-Chk1, is upregulated in QGY-7703 AEG-1 WT and KO cells
following low-dose IR. QGY-7703 cells were collected for whole protein lysate following
2.5Gy IR or release from double thymidine block (UT) at 30 minutes, 4 hours, 8 hours, and 12
hours. Lysates were then subjected to SDS-PAGE and probed for p-Chk1 and p-Chk2
expression. (A) Western blot images of p-Chk1 and p-Chk2, and loading controls (far right).
(B) Quantification of p-Chk1 (left) and p-Chk2 (right) expression relative to loading controls.
p-Chk2 expression was immediately and persistently upregulated in both AEG-1 WT and KO
cells after IR at 2.5Gy, while p-Chk1 was upregulated after 8 hours. Both proteins were
strongly upregulated after IR at 10Gy.
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Figure 10 HuH7 cells treated with low-dose IR do not show upregulated p-ATM, pATR, or p-BRCA1 signaling, but show upregulation of p-Chk2 and p-Chk1 expression
at later time-points. HuH7 cells were collected for whole protein lysate following IR
(2.5Gy) or release from double thymidine block (UT) at 30 minutes, 12 hours, 24 hours, and
36 hours. Lysates were then subjected to SDS-PAGE and probed for DDR signaling proteins.
(A-C) Western blot images (top) showing expression of total ATM and p-ATM (A), total
ATR and p-ATR (B), and p-BRCA1 (C), with quantification of the phosphorylated proteins
relative to internal loading controls (bottom). (D-E) Western blot images of p-Chk2 (D), and
p-Chk1 (E). (F) Representative western blot images of internal loading controls used for
quantification of expression. (G) Quantification of p-Chk2 (left) and p-Chk1 (right) relative to
GAPDH.
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Figure 11 Knockout of AEG-1 induces increased histone H2AX phosphorylation
following ionizing radiation. Representative confocal images of QGY-7703 cells stained
for gH2AX fluorescence, with either no treatment (A) or ionizing radiation at 2.5 Gy (B).
(C) gH2AX foci were quantified using ImageJ by finding maxima in each image. While
both AEG-1 KO and WT untreated cells showed a similar number of gH2AX foci, the
number of gH2AX foci was persistently and significantly increased in KO cells at all timepoints following IR.
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Figure 12 BCCIP expression is upregulated in AEG-1 KO mouse hepatic liver cells, but
not in DihXY or QGY-7703 AEG-1 KO cells. (A) Immunohistochemistry staining of mouse
hepatic liver cells, stained with anti-BCCIP antibody. (B) Western blot probed for BCCIP in
mouse hepatic whole protein lysates. Lanes 1-3 are wildtype for AEG-1; lanes 4-6 are AEG-1
KO; lane 7 is DihXY wildtype for AEG-1; lane 8 is DihXYA8 knockout of AEG-1. (C)
Representative immunofluorescence confocal images of DihXY cells (left) and QGY-7703
cells (right) stained with anti-AEG-1 (red), anti-BCCIP (green), and DAPI (blue).
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Figure 13 BCCIP expression is upregulated following ionizing radiation at 2.5 Gy in
QGY-7703, but not HuH7, cells. (A) QGY-7703 AEG-1 KO and WT cells were collected
at 30 mins, 4 hours, 8 hours, and 12 hours following either release from a double thymidine
block (UT), or treated with 2.5 Gy and then assessed for BCCIP expression via western
blotting. Protein expression was then quantified (right) relative to EF1a expression. (C)
Representative confocal images of cells to detect BCCIP immunofluorescence in QGY7703 UT and irradiated cells. UT cells were not synchronized for IF imaging. Cells were
stained with AEG-1 (red), BCCIP (green), and DAPI (blue).
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CHAPTER 5
DISCUSSION
HCC is a highly lethal disease and its limited treatment options are discouraging for advancedstage patients with non-resectable tumors. Resistance to the targeted kinase inhibitor, Sorafenib,
and to radiation therapy makes the situation even more grim. Regorafenib (StivargaÒ) has been
the only targeted therapy to be approved for treatment of HCC patients in recent years, and is
used in the context of patients whose tumors worsen during or after sorafenib treatment.
In recent years, targeted gene therapy is becoming increasingly focused on as a method of
overcoming issues with chemoresistance and radioresistance in multiple cancer types. However,
phase III clinical trials using various targeted therapies in HCC patients have failed due to
induced liver toxicity, low efficacy, or heterogeneity in the molecular background of HCC
tumors. Targeting AEG-1 mRNA expression with a nanoparticle-delivery system has shown
significant growth inhibition of orthotopic human xenografts in mice, indicating the protein
could be a promising molecular target for treating HCC patients48.
AEG-1 has been shown to be involved in the activation of numerous growth-promoting
pathways, is potently upregulated in HCC, and promotes hepatocarcinogenesis in both in vitro
and in vivo models10,14,16. The results from cell proliferation, invasion, and migration studies in
the present study confirm the already well-characterized phenotypic effects of AEG-1
upregulation. In HuH7 and QGY-7703 cells with deficient AEG-1 expression, there was a
significant decrease in in vitro matrigel invasion and wound closure. These assays are wellestablished methods to replicate the epithelial mesenchymal transition of carcinogenesis, which
is the process by which tumor cells metastasize outside of the primary tumor site49. In the QGY7703 cell line, there was also a significant reduction of AEG-1 KO cell survival in the colony
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formation assay, and a significant reduction in cell viability of AEG-1 KO cells in the MTT
assay. Although we did not observe reduced cell viability and cell survival in the HuH7 AEG-1
KO cell line, the KO cells showed significantly lower migration and invasion, which eliminates
cell proliferation as a confounding variable in the wound closure and matrigel invasion assays.
Furthermore, in the growth curve of the HuH7 cells, AEG-1 WT cells exhibit a sharp increase in
cell proliferation after 2 days of incubation. An explanation for these conflicting results is that
the HuH7 and QGY-7703 KO cell lines are phenotypically different from each other in their
capacity to proliferate due to the variability inherent in picking random clones produced from
CRISPR/Cas9. Regardless, from these results, and from western blot imaging of AEG-1
expression, we were confident that AEG-1 knockout was established in the cell line and was
producing the expected phenotypic effects.
Because cell proliferation was significantly reduced in the QGY-7703 AEG-1 KO cells, we
reasoned that cell cycle progression must also be delayed in the KO cell line. In maintenance of
the cell lines, QGY-7703 cells become confluent at least 1-2 days sooner than HuH7 or DihXY
cells. Double-thymidine block and cell cycle characterization have also previously been
established in the QGY-7703 cell line50. We therefore chose to use 0, 4, 8, and 12 hours as timepoints for cell cycle analysis in the QGY-7703 cell line. DihXY cells become confluent
approximately one day slower than QGY-7703 cells, and so 0, 4, 8, 12, 16, and 24 hours cell
cycle time-points were chosen for the this study. Finally, HuH7 cells reach confluency slowest
among the cell lines. We initially collected HuH7 cells every 6 hours for 48 hours for cell cycle
analysis (data not shown). Upon analysis, we identified that HuH7 cells complete a full cell cycle
at 36 hours. Subsequently, 0, 12, 24, and 36 hours were chosen for cell cycle analysis. Across the
DihXY, HuH7, and QGY-7703 cell lines, cell cycle progression was consistently reduced at all
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chosen time-points in the AEG-1 knockout clones. This deceleration in cell cycle progression
was more readily apparent in the QGY-7703 AEG-1 KO cells than in the other cell lines. One
explanation for this observation is that AEG-1 is expressed to a much higher degree in the QGY7703 AEG-1 WT cells compared to the HuH7 AEG-1 WT cells (see Yoo et al. 2009, Fig. 1A11),
indicating QGY-7703 cells may be more addicted to AEG-1 expression and therefore proliferate
faster.
The present study identifies AEG-1 as a potential target in sensitizing radioresistant HCC tumors
to radiation treatment. By using three different cell lines modeling HCC, we have shown that
knockout of AEG-1 promotes sensitization to radiation at a clinically relevant dosage of 2.5Gy.
While ionizing radiation at 10Gy proved completely cytotoxic to both AEG-1 WT and KO cells
across all cell lines, there was a significant reduction in cell viability in AEG-1 KO cells treated
with 2.5Gy. These results prompted us to assess protein expression of cell cycle regulatory
molecules and of signaling and effector molecules involved in the DNA damage response
pathway.
Appropriate DNA replication, cell cycle progression, and mitosis are all required for accurate
chromosome segregation and maintenance of genomic stability. Normally, cells that fail to abide
by these tightly regulated pathways are directed to apoptosis; however, cancer cells can finetune
expression of oncogenes or tumor suppressor genes to persist despite errors in mitosis or cell
cycle checkpoints. BCCIP is one of many proteins involved in the G1/G0 transition in the cell
cycle, along with spindle pole stabilization during mitosis. We were initially interested in
studying BCCIP expression in the context of AEG-1 knockout due to evidence that BCCIPa
directly interacts with AEG-1 in prostate tumor cells. Furthermore, Ash et al. provided evidence
that AEG-1 overexpression leads to proteasomal degradation of BCCIP, suggesting a potential
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role of AEG-1 expression in abrogating the G1/S checkpoint44. Although we observed increased
anti-BCCIP staining in IHC of AEG-1 KO mouse hepatic tissue samples compared to AEG-1
WT samples, we did not observe this difference in IF staining of DihXY or QGY-7703 cells.
BCCIP appeared to be primarily localized to the nucleus with faint signaling in the cytoplasm, as
seen in the DAPI-merged IF images. This localization is consistent with prior evidence that both
BCCIPa and BCCIPb are localized to the nucleus under confocal microscopy37. Furthermore,
we did not observe a noticeable change in BCCIP localization in either the untreated or irradiated
AEG-1 WT QGY-7703 cells. The present study therefore provides new evidence that BCCIP
localization is not affected by ionizing radiation in HCC cells.
After observing conflicting evidence of BCCIP signaling in IHC and IF assays, we sought to
analyze BCCIP protein expression in untreated and irradiated HCC cells. Unexpectedly, BCCIP
expression was increased in QGY-7703 AEG-1 WT cells at all time-points except for 12 hours
post-thymidine release, when compared to AEG-1 KO cells. Although FACS analysis of both
WT and KO cells at 12 hours show accumulation in G1/G0 phase, this decrease in BCCIP
expression in AEG-1 WT cells indicates a lack of G1/S checkpoint in the WT cells as they
continue unrestricted proliferation, which corroborates prior evidence that downregulation of
BCCIP in hepatocytes promotes G1/S transition and increases cell proliferation39. On the other
hand, BCCIP expression in the untreated HuH7 cell line was minimally upregulated in AEG-1
KO cells compared to WT cells at all time-points, except 24 hours, actually confirming the
findings of Ash et al44. Furthermore, BCCIP expression was markedly increased in the AEG-1
WT cells of both QGY-7703 and HuH7 cell lines at 30 minutes post-IR, but its expression was in
fact downregulated in the HuH7 cells, while upregulated in the QGY-7703 cells, compared to
their untreated counterparts, at this initial time-point. This conflicting pattern of BCCIP

54

expression in the QGY-7703 and HuH7 AEG-1 WT cell lines may be attributed to the TP53
mutational status of the HuH7 cell line. While QGY-7703 cells contain wildtype TP53, HuH7
cells overexpress a mutant p53 that exhibits a longer half-life – when compared to p53 of other
HCC cell lines and to normal liver cells – due to a point mutation in the coding region of
TP5351,52.
Because BCCIP has roles in both cell cycle regulation and homologous recombination repair, it
is difficult to attribute the upregulation of BCCIP in the irradiated QGY-7703 AEG-1 WT cells
to a specific pathway. Hence, the expression of BCCIP cannot be examined in a
compartmentalized manner. In a more comprehensive view of proteins involved in the DNA
damage response, we observed stronger, more rapid expression of p-ATM, p-ATR, and gH2AX
– all involved in signaling for initiation of homologous recombination repair – in the irradiated
AEG-1 WT cells than in the AEG-1 KO cells. Although p-ATM, gH2AX, and p-ATR in QGY7703 signaling in AEG-1 WT cells was initially stronger (30 minutes post-IR) compared to
AEG-1 KO cells, the expression pattern switched at subsequent time-points to be increased in
AEG-1 KO cells compared to WT cells. Similarly, p-BRCA1 and p-Chk1 expression showed a
sharp increase in HuH7 irradiated AEG-1 WT cells at 24 hours post-IR, and their expression was
higher in HuH7 irradiated AEG-1 KO cells at 36 hours. Analysis of the downstream checkpoint
kinase p-Chk2 showed that its expression was increased in the QGY-7703 AEG-1 WT cells at 30
minutes until 8 hours post-IR at 2.5Gy, after which the irradiated AEG-1 KO cells showed
increased expression. This can be explained by an initial, rapid activation of ATM, ATR,
BRCA1, and gH2AX signaling, as observed in the AEG-1 WT cells at 30 minutes post-IR, which
is subsequently followed by more rapid activation of p-Chk2 and p-Chk1 in the AEG-1 WT
cells. Therefore, there is reliable evidence that AEG-1 WT cells induce the DDR more rapidly,
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and is a possible mechanism by which DSB’s are repaired more efficiently by AEG-1
overexpressing cells to protect HCC from low-dose ionizing radiation.
A potential limitation of our findings is that p-Chk1 and gH2AX signaling can be indicators of
the DNA damage response, but are not specific to this process51. Immunofluorescence staining of
gH2AX is used to demonstrate DDR foci in cells treated with IR. In response to DNA damage,
gH2AX is phosphorylated on its Ser139 residue and signals for mediator of DNA damage
checkpoint 1 (MDC1) to directly bind gH2AX at its BRCT domain. This is required for
recruitment of DDR complexes such as 53BP1 to repair damaged DNA53,54. However, H2AX
phosphorylation is also implicated in replication stress and checkpoint abrogation55,56.
Nevertheless, because we also observed an upregulation of p-ATM and p-chk2 expression in
conjunction with gH2AX signaling, we provide convincing data that DSB-induced signaling is
initiated in QGY-7703 AEG-1 WT cells more rapidly than in KO cells.
In the present study we observed p-ATR expression was upregulated in AEG-1 WT cells after IR
at 2.5Gy. In fact, p-ATR expression was consistently upregulated in QGY-7703 AEG-1 WT cells
at all time-points following IR at 2.5Gy. The results were not as remarkable in HuH7 AEG-1 WT
cells, but we did observe marked, increased upregulation of p-ATR expression at 24 hours postIR when compared to AEG-1 KO cells. We therefore became interested in the possibility of WT
AEG-1 cells protecting cells from low-dose ionizing radiation through increased replication fork
stabilization. Cancer cells have higher baseline rates of replication due to oncogenic drivers and
therefore may have increased incidence of replicative stress in the absence of genotoxic
stressors52. In the context of HCC, non-transformed hepatocytes are quiescent and normally
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divide only rarely, making them susceptible to replicative stress57. Hepatic cells may therefore
have increased replication fork protection at a basal level, even prior to carcinogenesis.
DNA replication stress encompasses any endogenous or exogenous stressor that can induce
replication fork stalling or damage, generating exposed single-stranded DNA and inducing the
intra-S-phase checkpoint. Replication stress is sensed by ATR, which autophosphorylates and
relays the signal to the Chk1 effector kinase. BRCA1, BRCA2, and the Fanconi anemia family of
proteins are required for MRE11 nuclease to protect nascent DNA strands at stalled replication
forks. While they use very similar proteins in their processes, HRR and replication fork
protection are functionally separate58,59. Topoisomerase IIβ-binding protein 1 (TopBP1) activates
ATR and is required for resolving replication stress to prevent formation of 53BP1 nuclear
bodies. Ultimately, ATR activation in response to replication stress is fundamental to protect
genomic integrity and repair stalled replication forks prior to mitotic entry. Therefore, an intra-Sphase checkpoint is induced while replication forks are repaired in the presence of stress.
Replication stress can be a result of too few origins of replication or insufficient activation of
these origins; activation of too many origins of replication, which can lead to depletion of
histones or DNA binding protein RPA and subsequently the collapse of replication forks.
Replication stress can also be induced by exogenous stressors, including UV-light or genotoxic
agents - such as hydroxyurea, cisplatin, mitomycin C, and camptothecin. There is also mounting
evidence that activation of oncogenes results in replication stress by affecting origin firing,
nucleotide depletion, or changing temporal stability of the cell cycle 61,62. The present findings
identify a previously unexplored role of AEG-1 expression in protecting HCC cells from
radiation therapy through upregulation of p-ATR. Further investigation needs to be conducted on
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AEG-1 in protecting replication forks before we can positively conclude that this is another
pathway through which AEG-1 induces radioresistance.
Recently, whole genome sequencing, whole exome sequencing, and RNA-sequencing of 751
distinct HCC tissues identified a subgroup of HCC tumors that contain mutated CCNE1
(encoding cyclin E) or CCNA2 (encoding cyclin A2) from patients who developed HCC in a
non-cirrhotic background. The lab identified recurrent CCNA2 fusions and CCNE1 promoter
region rearrangements60. Cancers with such mutational backgrounds are characterized by high
amounts of replication stress due to increased proliferation rates62. The present study showed
cyclin E upregulation in untreated HuH7 AEG-1 KO cells at 12, 24, and 36 hours post-thymidine
release, and in irradiated AEG-1 KO cells at 30 minutes, 12, and 36 hours post-IR at 2.5Gy. On
the other hand, cyclin E protein expression was upregulated in untreated QGY-7703 AEG-1 WT
cells at 30 minutes and 4 hours post-thymidine release, while AEG-1 KO cells had increased
expression at 8 and 12 hours. In both AEG-1 WT and KO QGY-7703 cells, cyclin E was
consistently upregulated at all time-points at both 2.5 and 10Gy dosages. Cyclin E expression
patterns in QGY-7703 cells, along with our observations of upregulated p-ATR signaling in
QGY-7703 cells across all time-points, is consistent with prior reports that cyclin E upregulation
is associated with ATR upregulation in HCC64. Furthermore, evidence in our study of both cyclin
E and p-ATR overexpression in irradiated QGY-7703 cells point to induction of replication
stress in these cells in response to IR, as cyclin E regulation is implicated in appropriate origin of
replication firing55.
Along the same line of reasoning, our observations of cyclin E upregulation, yet slowed cell
cycle progression, in the irradiated QGY-7703 cells can be attributed to p-Chk2 upregulation. PChk2 has been shown to inhibit enzymatic activity of the cyclin E/Cdk2 complex21. As we
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observed a strong increase in p-Chk2 expression in the irradiated QGY-7703 cells, there is a
possibility that p-Chk2 is interacting with the cyclin E/Cdk2 complex to delay cell cycle
progression, while transcription of CC2NE1 is upregulated.
An unexpected finding of this study was upregulation of AEG-1 expression in QGY-7703 cells
in response to ionizing radiation, as was evidenced by both western blot analysis and confocal
microscopy. A current literature search only shows one prior study of AEG-1 expression in the
context of ionizing radiation. However, this study focused on preventing recurrence of distant
metastatic tumors in rectal cancer patients through AEG-1 knockdown66. The present study
therefore provides evidence that AEG-1 itself is upregulated in response to ionizing radiation in
HCC cells, along with affecting protein expression of DDR kinases. There are multiple ways
through which protein expression of AEG-1 is upregulated in HCC: genomic amplification, posttranslational monoubiquitination, transcriptional activation by c-myc, downregulation of miR375, and/or binding of cytoplasmic polyadenylation element-binding protein 1 (CPEB1) to AEG1 mRNA to activate its translation67,68. The mechanism by which AEG-1 is upregulated
following IR treatment can be the focus of a future project.
A limitation of the present study is that use of the CRISPR/Cas9 system to knockout a gene
comes with several drawbacks. One of these drawbacks is potential off-target effects that the
vector may induce in the selected clones. Until full genomic profiling is conducted on the cell
lines, the possibility of insertional or deletion mutations in genes other than the intended target,
AEG-1, must be considered. Furthermore, the clones selected for these studies are randomly
generated and selected, and each clone may be slightly phenotypically or genetically different
from another. However, as previously described, AEG-1 expression can be upregulated in a
number of ways, including through genomic amplification. Complete deletion of the gene in
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three diverse HCC cell lines was a feat in and of itself, and has provided considerable critical
insight needed to address the aims established for this project. These concerns can be addressed,
and the results of this study validated, by selecting multiple AEG-1 knockout clones from each
cell line in future projects, or replicating the results in vivo using the Cre/lox conditional
knockout system to abrogate AEG-1 expression.
We conclude that AEG-1 expression protects HCC cells from low-dose ionizing radiation
through two mechanisms: 1) initiating the DNA damage response rapidly and efficiently; and 2)
increasing replication fork stabilization in the face of replication stress. The scope of this study
did not fully address the mechanistic role of AEG-1 expression in resolving stalled replication
forks or in promoting more rapid DSB repair, and therefore needs to be clarified in future
studies. Regardless, the results described here do give us a promising method of sensitizing
radioresistant HCC tumors through abrogation of AEG-1 expression.
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CHAPTER 6
FUTURE DIRECTIONS
Although our results are exciting, they must be replicated in vivo to establish validity in their
ability to be translated to the clinic. A Cre/lox model of liver-specific AEG-1 knockout in mice,
with subsequent DEN-induced liver tumor formation, can be used to demonstrate replicability of
sensitization to ionizing radiation in AEG-1 deficient HCC cells. Another viable method would
be to use nanoparticle delivery of AEG-1 siRNA (as described by Rajasekaran et al. 201548) in
combination with radiation therapy in mice containing xenografts of QGY-7703 or HuH7
parental cell lines48.
A major question we are left with after the results described here is whether p-ATR upregulation
induced by AEG-1 expression in irradiated HCC cells is due to replication fork stabilization.
Activated ATR has diverse functions in both DSB and SSB repair; therefore, it is crucial that we
identify in which functional pathway p-ATR is being used to protect HCC cells from IR. There
are several ways to identify activation of the replication stress response. Possibly the simplest
method is the cell cycle restart assay, in which cells are treated with hydroxyurea to deplete
dNTP’s. Other methods involve quantification of replication foci or origins. IF staining of IdU –
a thymidine analog – can be used to quantify replication foci in early S-phase cells. Additionally,
DNA fiber analysis quantifies firing of replication origins and distances between origins69. A
more complex but comprehensive method would be to analyze the genetic expression patterns of
replication-stress-associated genes in both untreated and irradiated AEG-1 KO and WT cells. A
recent paper used a cell line with diminished ATR expression to generate a replication stress
defect signature through microarray analysis. A similar model could be created by knockdown of
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ATR, via short hairpin RNA, in HuH7 and QGY-7703 cell lines to compare against the
replication stress gene signature of irradiated cells70.
Several inhibitors that target proteins involved in the cell cycle have been previously studied in
HCC models. The Wee1 kinase inhibitor AZD1775 has recently been shown to sensitize HCC
cells to radiation treatment. Wee1 is a Ser/Thr kinase that was originally identified in the fission
yeast S. pombe. The human homologues for Wee1 are Wee1A and Wee1B. Wee1 kinase is
involved in G2 checkpoint regulation and replication initiation via inhibition of CDK1, and
Wee1 kinase activity is implicated in preventing replication stress and inappropriate DNA
replication. In Hep3B and HuH7 HCC cell lines, Cdk1 phosphorylation – which is an indicator
of G2 arrest – was increased when treated with ionizing radiation, but this arrest was absent
when radiation was combined with AZD1775 treatment44. Another recent paper has also
reviewed evidence that a combination of ATR and Wee1 kinase inhibitors can target both
replication fork stabilization and HRR in cancerous cells29. Although phase I and II clinical trials
are currently underway to target ATR, CHK1, and WEE1, these are not being studied in the
context of HCC62. Therefore, a study using a panel of ATR, Wee1, and Chk1 kinase inhibitors in
our model can provide insight as to whether knockout of AEG-1 induces increased sensitivity of
HCC cells to these inhibitors, as well as provide rationale for using such inhibitors in an in vivo
model of HCC. The results could also clue us into how AEG-1 interacts with these diverse
signaling proteins to induce radioresistance.
Aurora kinases are serine/threonine kinases involved in maintaining appropriate cell cycle
progression and genomic stability. Inhibiting aurora kinases induces a postmitotic checkpoint
and accumulates cells in a pseudo-G1 state that requires p53. Prior studies have shown
aggressive HCC with poor prognosis correlated with overexpression of aurora kinases A and
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B71,72. The same lab that identified Aurora kinases A and B overexpression in HCC then showed
that HCC can be sensitized to radiation when treated with the broad aurora kinase inhibitor VE46573. Although expression of aurora kinases were not analyzed in the present study, observing
the effect of wide-spectrum aurora kinase inhibition in an AEG-1 KO model could be another
avenue of investigating how AEG-1 interacts with cell cycle regulators.
In addition, the exact mechanism through which AEG-1 interacts with the DNA damage
response is still unclear. AEG-1 is a potent upregulator of the PI3K/Akt and RAF-1-MEK1/2ERK1/2 pathways. These signaling pathways are pro-survival and have been shown to be
activated in response to ionizing radiation in various cancer cell types. Ionizing radiation at low,
clinically-relevant doses (1-2 Gy) induces phosphorylating activation of epidermal growth factor
receptors ERBB1 and HER1 due to generation of reactive oxygen species and reactive nitrogen
species in the mitochondria, which reduce protein tyrosine phosphatase activity of ERBB1 and
HER1. This reaction occurs during the initial response to ionizing radiation. Following several
hours, it is hypothesized that ERK1/2 and Akt signaling can change cyclin expression profiles,
along with affecting levels of pro-cell survival molecules Bcl-2, Bcl-XL, MCL-1, c-FLIP, XIAP,
IAP1, and pro-apoptotic molecules BAD and BIM. This in turn allows for survival of a small
subset of the cell population to continue actively proliferating despite radiation treatment74,75,76.
There is also evidence that tumors containing H-RAS, K-RAS, or N-RAS mutations may also be
protected from ionizing radiation because they too can activate the PI3K pathway
inappropriately. Targeting PI3K signaling using small molecule inhibitors sensitizes these tumor
cells to ionizing radiation77. In order to discern whether knockout of AEG-1 itself has a
functional effect on reducing the DNA damage response, or if dampening of PI3K/Akt/ERK1/2
signaling as a result of AEG knockout induces sensitization to radiation treatment, it would be
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prudent to repeat the radiation studies in in vitro models with depletion of PI3K/Akt signaling in
AEG-1 WT clones, or reconstitution of the pathway in AEG-1 KO clones.
Finally, because our findings of BCCIP expression in the context of AEG-1 expression conflict
with both the literature44 and within our study between the QGY-7703 and HuH7 cell lines, it is
evident that replicating Ash et al.’s co-immunoprecipitation of AEG-1 with BCCIP must be
conducted in multiple HCC cell lines. Further investigation of this interaction between AEG-1
and BCCIP can clarify the role of BCCIP function in the context of AEG-1 overexpressing HCC
cells, as well as identify possible heterogeneity in their interaction across various HCC cell lines.
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